Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

413 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prasugrel 5 mg inhibits platelet P-selectin and GPIIb-IIIa expression in very elderly and non elderly: results from the GENERATIONS trial, a pharmacodynamic study in stable CAD patients.
Wagner H, Lood C, Borna C, Gidlöf O, Truedsson L, Brown P, Zhou C, Winters K, Jakubowski JA, Erlinge D. Wagner H, et al. Among authors: winters k. J Thromb Thrombolysis. 2016 Oct;42(3):369-75. doi: 10.1007/s11239-016-1372-1. J Thromb Thrombolysis. 2016. PMID: 27165280 Clinical Trial.
Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial.
Erlinge D, Ten Berg J, Foley D, Angiolillo DJ, Wagner H, Brown PB, Zhou C, Luo J, Jakubowski JA, Moser B, Small DS, Bergmeijer T, James S, Winters KJ. Erlinge D, et al. J Am Coll Cardiol. 2012 Nov 13;60(20):2032-40. doi: 10.1016/j.jacc.2012.08.964. Epub 2012 Oct 17. J Am Coll Cardiol. 2012. PMID: 23083774 Free article.
Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients.
Erlinge D, Gurbel PA, James S, Lindahl TL, Svensson P, Ten Berg JM, Foley DP, Wagner H, Brown PB, Luo J, Zhou C, Moser BA, Jakubowski JA, Small DS, Winters KJ, Angiolillo DJ. Erlinge D, et al. J Am Coll Cardiol. 2013 Aug 13;62(7):577-83. doi: 10.1016/j.jacc.2013.05.023. Epub 2013 Jun 7. J Am Coll Cardiol. 2013. PMID: 23747759 Free article. Clinical Trial.
Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients.
Wagner H, Angiolillo DJ, Ten Berg JM, Bergmeijer TO, Jakubowski JA, Small DS, Moser BA, Zhou C, Brown P, James S, Winters KJ, Erlinge D. Wagner H, et al. J Thromb Thrombolysis. 2014;38(2):127-36. doi: 10.1007/s11239-013-0987-8. J Thromb Thrombolysis. 2014. PMID: 24043374 Clinical Trial.
The Rationale for and Clinical Pharmacology of Prasugrel 5 mg.
Jakubowski JA, Erlinge D, Alexopoulos D, Small DS, Winters KJ, Gurbel PA, Angiolillo DJ. Jakubowski JA, et al. Am J Cardiovasc Drugs. 2017 Apr;17(2):109-121. doi: 10.1007/s40256-016-0202-3. Am J Cardiovasc Drugs. 2017. PMID: 27854064 Review.
413 results